Activity of posaconazole in the treatment of central nervous system fungal infections

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 4, 2005, Pages 745-755

  Pitisuttithum, Punnee ^a   Negroni, Ricardo ^b   Graybill, John R ^c   Bustamante, Beatriz ^d   Pappas, Peter ^e   Chapman, Stanley ^f   Hare, Roberta S ^g   Hardalo, Catherine J ^g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Hospital FJ Muñiz   (Argentina)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cryptococcal infections; Invasive; Salvage treatment; Triazoles

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; POSACONAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC DIARRHEA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FUNGAL MENINGITIS; FUNGAL VIRULENCE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; OPEN STUDY; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 27144459842     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki288     Document Type: Article

References (58)

1. Saag MS, Graybill FJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-8.
2. Maschke M, Dietrich U, Prumbaum M et al. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1167-76.
3. Mellinghoff IK, Winston DJ, Mukwaya G et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34: 1648-50.
4. Ponton J, Ruchel F, Clemons KV et al. Emerging pathogens. Med Mycol 2000; 38 (Suppl. 1): 225-36.
5. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-9.
6. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17: 837-42.
7. French N, Gray K, Watera C et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16: 1031-8.
8. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
9. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet 2004; 363: 1764-7.
10. Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5: 67-79.
11. Galgiani JN, Ampel NM, Catanzaro A et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30: 658-61.
12. Troke PF, Schwartz S, Ruhnke M et al. Voriconazole (VRC) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): A retrospective analysis. In Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract M-1755, p. 476. American Society for Microbiology, Washington, DC, USA, 2003.
13. Baden LR, Katz JT, Fishman JA et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-7.
14. Dannaoui E, Meletiadis J, Mouton JW et al. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
15. Marty FM, Cosimi L, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-2.
16. Pfaller MA, Messer SA, Hollis RJ et al. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 2862-4.
17. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
18. Gonzalez GM, Tijerina R, Najvar LK et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002; 46: 1352-6.
19. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-3.
20. Gonzalez GM, Tijerina R, Najvar LK et al. Activity of posaconazole against Pseudallescheria boydii: In vitro and in vivo assays. Antimicrob Agents Chemother 2003; 47: 1436-8.
21. Meletiadis J, Meis JF, Mouton JW et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-8.
22. Sutton DA. Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr Opin Infect Dis 2002; 15: 575-82.
23. Bocanegra RA, Johnson EM, Najvar LK et al. Use of novel antifungals in treatment of murine phaeohyphomycosis caused by Wangiella dermatitidis (WD). In Program and Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Abstract F-86, p. 160. American Society for Microbiology, Washington, DC, USA, 1997.
24. Gonzalez GM, Tijerina R, Najvar LK et al. Therapeutic efficacy of posaconazole (POSA) in amurine Pseudallescheria boydii (Pb) infection. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract J-1615, p. 391. American Society for Microbiology, Washington, DC, USA, 2003.
25. Al-Abdely H, Najvar L, Bocanegra R et al. SCH-56592 (SCH) therapy of experimental murine cerebral phaeohyphomycosis due to Cladophialophora bantiana (CB). In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J69, p. 470. American Society for Microbiology, Washington, DC, USA, 1998.
26. Kirkpatrick WR, McAtee RK, Fothergill AW et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 780-2.
27. Perfect JR, Cox GM, Dodge RK et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910-3.
28. Herrin K. Control of disseminated coccidioidomycosis by oral posaconazole in a chimpanzee (Pan troglodytes). Mycoses 2005; in press.
29. Barchiesi F, Spreghini E, Schimizzi AM et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004; 48: 3312-6.
30. Ezzet F, Wexler D, Courtney R et al. Comparative bioavailability of oral posaconazole (POS) in different dosage regimens: A population pharmacokinetic analysis. In Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2003. Abstract A-1565, p. 29. American Society for Microbiology, Washington, DC, USA. 2003.
31. Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-95.
32. Ullmann AJ, Cornely OA, Burchardt A et al. Safety and efficacy of posaconazole (POS) in a pharmacokinetic study in patients with febrile neutropenia (FN) or refractory invasive fungal infections (rIFI). In Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2003. Abstract M-1257, p. 474. American Society for Microbiology, Washington, DC, USA, 2003.
33. Restrepo A, Clark B, Graham D et al. Treatment of histoplasmosis with posaconazole. In Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2003. Abstract M-973, p. 449. American Society for Microbiology, Washington, DC, USA, 2003.
34. Negroni R, Tobon AM, Bustamante M et al. Posaconazole (POS) treatment of mycetoma and chromoblastomycosis. In Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2003. Abstract M-976, p. 449. American Society for Microbiology, Washington, DC, USA, 2003.
35. Graybill JR, Raad I, Negroni R et al. Posaconazole (POS) long-term safety in subjects with invasive fungal infections (IFIs). In Program and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Therapy, Washington, DC, USA, 2004. Abstract M-1025. American Society for Microbiology, Washington, DC, USA, 2004.
36. Tissot-Dupont H, Branger S, Pham T et al. Aspergillus flavus chondrocostal osteomyelitis treated with posaconazole: A case study. In Proceedings of the Joint meeting of the Ninth Congress of the European Confederation of Medical Mycology (ECMM) and the Seventh Trends in Invasive Fungal Infections (TIFI), Amsterdam, The Netherlands, 2003. Abstract P104. Monduzzi Editore, Bologna, Italy, 2003.
37. Negroni R, Helou SH, Petri N et al. Case study: Posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004; 38: E15-20.
38. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
39. Al-Abdely HM, Alkhunaizi A, Al-Tawfiq J et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005; 43: 91-5.
40. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
41. Chotmongkol V, Jitpimolmard S. Treatment of cryptococcal meningitis with triple combination of amphotericin B, flucytosine and itraconazole. Southeast Asian J Trop Med Public Health 1995; 26: 381-3.
42. Chotmongkol V, Jitpimolmard S. Itraconazole in the treatment of cryptococcal meningitis. J Med Assoc Thai 1992; 75: 85-8.
43. Chotmongkol V, Jitpimolmard S. Treatment of cryptococcal meningitis with combination itraconazole and flucytosine. J Med Assoc Thai 1994; 77: 253-6.
44. Leenders ACAP, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1463-71.
45. Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-21.
46. Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patientswith AIDS. AIDS 1993; 7: 829-35.
47. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
48. Larsen RA, Bozzette SA, Jones BE et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741-5.
49. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: A randomized trial. Ann Intern Med 1990; 113: 183-7.
50. Chotmongkol V, Sukeepaisarncharoen W, Thavornpitak Y. Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. J Med Assoc Thai 1997; 80: 416-25.
51. De GJ, Portegies P, Tiessens G et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992; 6: 185-90.
52. Snow RM, Dismukes WE. Cryptococcal meningitis: Diagnostic value of cryptococcal antigen in cerebrospinal fluid. Arch Intern Med 1975; 135: 1155-7.
53. Barenfanger J, Lawhorn J, Drake C. Nonvalue of culturing cerebrospinal fluid for fungi. J Clin Microbiol 2004; 42: 236-8.
54. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
55. Archibald LK, Tuohy MJ, Wilson DA et al. Antifungal susceptibilities of Cryptococcus neoformans. Emerg Infect Dis 2004; 10: 143-5.
56. Pfaller MA, Messera SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2004; 48: 201-5.
57. Barchiesi F, Arzeni D, Fothergill AW et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44: 226-9.
58. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: A review of 101 cases. Clin Infect Dis 2004; 38: 206-16.